Raymond James Financial Services Advisors, Inc. Cidara Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
SELL
$0.64 - $0.92 $840 - $1,208
-1,314 Reduced 1.67%
77,553 $71,000
Q4 2023

Jan 16, 2024
SELL
$0.68 - $0.97 $171 - $244
-252 Reduced 0.32%
78,867 $62,000
Q3 2023

Oct 24, 2023
BUY
$0.77 - $1.16 $12,252 - $18,457
15,912 Added 25.17%
79,119 $74,000
Q2 2023

Jul 25, 2023
SELL
$1.01 - $1.42 $6,512 - $9,156
-6,448 Reduced 9.26%
63,207 $71,000
Q1 2023

Apr 14, 2023
SELL
$0.75 - $1.98 $3,000 - $7,920
-4,000 Reduced 5.43%
69,655 $88,000
Q4 2022

Feb 08, 2023
SELL
$0.48 - $13.08 $7,214 - $196,605
-15,031 Reduced 16.95%
73,655 $55,000
Q3 2022

Oct 25, 2022
BUY
$0.45 - $13.0 $876 - $25,311
1,947 Added 2.24%
88,686 $56,000
Q2 2022

Aug 12, 2022
BUY
$0.43 - $0.91 $198 - $419
461 Added 0.53%
86,739 $42,000
Q1 2022

May 11, 2022
BUY
$0.67 - $1.39 $7,532 - $15,627
11,243 Added 14.98%
86,278 $72,000
Q4 2021

Feb 08, 2022
SELL
$1.18 - $2.18 $16,882 - $31,189
-14,307 Reduced 16.01%
75,035 $95,000
Q3 2021

Nov 02, 2021
SELL
$1.48 - $2.35 $7,395 - $11,742
-4,997 Reduced 5.3%
89,342 $200,000
Q2 2021

Aug 11, 2021
BUY
$1.87 - $2.7 $14,277 - $20,614
7,635 Added 8.81%
94,339 $191,000
Q1 2021

May 14, 2021
SELL
$2.06 - $3.01 $5,716 - $8,352
-2,775 Reduced 3.1%
86,704 $231,000
Q4 2020

Feb 12, 2021
SELL
$1.99 - $3.25 $17,115 - $27,953
-8,601 Reduced 8.77%
89,479 $179,000
Q3 2020

Nov 04, 2020
SELL
$2.85 - $4.1 $11,243 - $16,174
-3,945 Reduced 3.87%
98,080 $280,000
Q2 2020

Jul 17, 2020
BUY
$2.39 - $4.0 $243,839 - $408,100
102,025 New
102,025 $376,000
Q1 2020

Apr 21, 2020
SELL
$1.74 - $4.26 $216,148 - $529,189
-124,223 Closed
0 $0
Q4 2019

Feb 12, 2020
BUY
$1.77 - $3.84 $38,200 - $82,874
21,582 Added 21.03%
124,223 $477,000
Q3 2019

Nov 07, 2019
SELL
$1.25 - $2.35 $31,098 - $58,465
-24,879 Reduced 19.51%
102,641 $205,000
Q2 2019

Aug 06, 2019
SELL
$1.49 - $2.94 $26,375 - $52,043
-17,702 Reduced 12.19%
127,520 $214,000
Q1 2019

May 06, 2019
SELL
$2.35 - $3.27 $292,927 - $407,605
-124,650 Reduced 46.19%
145,222 $385,000
Q4 2018

Feb 11, 2019
BUY
$2.1 - $4.5 $120,342 - $257,877
57,306 Added 26.96%
269,872 $634,000
Q3 2018

Nov 14, 2018
BUY
$3.7 - $5.25 $162,592 - $230,706
43,944 Added 26.06%
212,566 $935,000
Q2 2018

Jul 30, 2018
BUY
$3.75 - $6.05 $373,601 - $602,743
99,627 Added 144.4%
168,622 $877,000
Q1 2018

Apr 16, 2018
BUY
$4.0 - $8.15 $156,860 - $319,602
39,215 Added 131.68%
68,995 $276,000
Q4 2017

Feb 09, 2018
BUY
$6.35 - $8.75 $36,798 - $50,706
5,795 Added 24.16%
29,780 $203,000
Q3 2017

Oct 26, 2017
BUY
$5.75 - $8.1 $37,375 - $52,650
6,500 Added 37.17%
23,985 $194,000
Q2 2017

Aug 15, 2017
BUY
N/A
17,485
17,485 $131,000

About Cidara Therapeutics, Inc.

CDTX Quotes by TradingView
  • Ticker CDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,075,696
  • Market Cap $1.43B
  • Description
  • Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...
More about CDTX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email